Become A Featured Company

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

Ryan Allway

December 7th, 2021

Psychedelics

TAMPA, FLA. (PRWEB) DECEMBER 07, 2021

Psilera Inc. (“Psilera”), a Florida-based biotechnology company developing non-hallucinogenic derivatives of psychedelic compounds and outpatient delivery methods for the treatment of anxiety, substance abuse, and PTSD, is thrilled to receive positive results from in vivo preclinical studies. A modified DMT derivative, PSIL-002, was safe, well-tolerated, and without hallucinogenic effects at all administered dosages between 0.5 to 100 mg/kg in mice.

 

The head-twitch-response (“HTR”) assay in mice is a well-established and preferred method of assessing hallucinogenic effects in animals. Astonishingly, no dose of PSIL-002 induced the HTR as compared to the positive control, psilacetin (“4-AcO-DMT”), a psilocybin mimic. Other psychedelics like psilocybin and DMT often produce the HTR at doses from 1-10 mg/kg or as low as 0.05-0.1 mg/kg for LSD, further demonstrating the non-hallucinogenic potential of PSIL-002 and broader range for therapeutic dosing.

 

Psilera’s patent-pending new chemical entity (“NCE”) library was designed to maintain the positive mood benefits of current psychedelics while reducing hallucinations and cardiotoxicity. Psilera has carefully selected their NCEs aided by its proprietary BRAIN technology platform which virtually screens and filters compounds for psychedelic potential at multiple receptors, especially 5-HT2A. Reducing the hallucinogenic effects represent a compelling opportunity to develop therapeutic drugs which can be administered outside of a clinical setting, expanding the total addressable market.

 

“This biological data is key to our vision of reducing side effects such as hallucinations while further optimizing classical psychedelics into next-generation drugs,” said Dr. Chris Witowski, Co-Founder and CEO of Psilera, Inc. “Compounds like PSIL-002 have the potential to reach new patient populations in need with greater access than current models, especially for those suffering from conditions where hallucinations may be undesirable. We’re delighted to validate the results from our BRAIN platform and look forward to further data readouts to bolster our dataset and intellectual property strategy.”

 

Further in vivo studies with PSIL-002 will assess the antidepressant, anxiolytic, and anti-addictive properties specifically targeting alcohol consumption. A compound shown to reduce substance abuse, 4-AcO-DMT,1 as well as five additional patent-pending NCEs will be screened in the same battery of translational behavioral assays with data readouts over the next several months.

 

About Psilera – Psilera Inc. is a psychedelic-based biotechnology company developing its proprietary neuromodulator pipeline to target mental health disorders. With a proven and award-winning executive team, Psilera leverages research strengths from the pharmaceutical and cannabis industries to repurpose psychoactive natural products into patient-centric treatments. New formulations tailoring the therapeutic effects of DMT will improve treatment scalability and patient compliance further expanding addressable markets. Psilera’s technology platform (BRAIN) will identify next-generation compounds with modified psychedelic and therapeutic effects in the areas of mood, cognitive, and substance use disorders.

 

1Vargas-Perez, Hector, et al. “A Single Administration of the Hallucinogen, 4-Acetoxy-Dimethyltryptamine, Prevents the Shift to a Drug-Dependent State and the Expression of Withdrawal Aversions in Rodents.” European Journal of Neuroscience. 45, 11, 2017, doi:10.1111/ejn.13572.

 

 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading